Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Takeda Pharmaceutical Company ( (TAK) ).
Takeda Pharmaceutical Company recently reported on its share repurchase activities for the period from April 1 to April 30, 2025. During this time, the company repurchased a total of 11,823,500 shares, amounting to approximately 49.98 billion JPY. This activity is part of a broader repurchase plan approved by the Board of Directors, which aims to enhance shareholder value and optimize the company’s capital structure. As of the end of April 2025, Takeda has repurchased a cumulative total of 23,367,100 shares, representing significant progress in its repurchase program.
The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.
Spark’s Take on TAK Stock
According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.
Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.
To see Spark’s full report on TAK stock, click here.
More about Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Tokyo, Japan. It operates in the healthcare industry, focusing on developing and providing pharmaceutical products and services. The company is known for its innovative medicines and therapies, catering to a wide range of medical needs across various therapeutic areas.
Average Trading Volume: 2,075,856
Technical Sentiment Signal: Buy
Current Market Cap: $43.07B
For an in-depth examination of TAK stock, go to TipRanks’ Stock Analysis page.